Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhuoxin Sun

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Plos One|April 18, 2015
Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaAlessandra Cesano, Cheryl L Willman, Kenneth J Kopecky, et al.
Leukemia Research|May 29, 2017
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic TrialsStephen A Strickland, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
Blood Cancer Journal|September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Blood Cancer Journal|July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Cancer Cell|December 7, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al.
Leukemia|April 13, 2026
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patientsYaseswini Neelamraju, Franck Rapaport, Jorge A Gandara, et al.
Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Plos One|April 18, 2015
Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaAlessandra Cesano, Cheryl L Willman, Kenneth J Kopecky, et al.
Leukemia Research|May 29, 2017
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic TrialsStephen A Strickland, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
Blood Cancer Journal|September 23, 2022
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Blood Neoplasia|March 27, 2026
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trialJames M Foran, Zhuoxin Sun, Selina M Luger, et al.
Blood Cancer Journal|July 5, 2023
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999Franck Rapaport, Kenneth Seier, Yaseswini Neelamraju, et al.
Cancer Cell|December 7, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al.
Leukemia|April 13, 2026
Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patientsYaseswini Neelamraju, Franck Rapaport, Jorge A Gandara, et al.
Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.
Blood Advances|June 2, 2023
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysisSara Zarnegar-Lumley, Todd A Alonzo, Robert B Gerbing, et al.
Pageof 8